TY - JOUR
T1 - Recent developments in multiple sclerosis therapeutics
AU - Spain, Rebecca I.
AU - Cameron, Michelle H.
AU - Bourdette, Dennis
N1 - Funding Information:
RIS has no competing interests. MHC has received honoraria for speaking from Teva Neuroscience. DB has research grants from the National Institutes of Health, the Department of Veterans Affairs and the National Multiple Sclerosis Society. DB has also received honoraria for speaking/consulting or unrestricted educational grants, from Teva Neuroscience, Biogen Idec, EMD Serono and Bayer USA.
PY - 2009/12/7
Y1 - 2009/12/7
N2 - Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally considered to be an inflammatory, autoimmune, demyelinating disease of the central nervous system. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. These approaches, including high-dose corticosteroids for acute relapses and long-term use of parenteral interferon-β, glatiramer acetate or natalizumab for disease modification, are at best moderately effective. Growing evidence supports that, while an inflammatory pathology characterizes the early relapsing stage of multiple sclerosis, neurodegenerative pathology dominates the later progressive stage of the disease. Multiple sclerosis disease-modifying therapies currently in development attempt to specifically target the underlying pathology at each stage of the disease, while avoiding frequent self-injection. These include a variety of oral medications and monoclonal antibodies to reduce inflammation in relapsing multiple sclerosis and agents intended to promote neuroprotection and neurorepair in progressive multiple sclerosis. Although newer therapies for relapsing MS have the potential to be more effective and easier to administer than current therapies, they also carry greater risks. Effective treatments for progressive multiple sclerosis are still being sought.2009 Spain et al; licensee BioMed Central Ltd.
AB - Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally considered to be an inflammatory, autoimmune, demyelinating disease of the central nervous system. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. These approaches, including high-dose corticosteroids for acute relapses and long-term use of parenteral interferon-β, glatiramer acetate or natalizumab for disease modification, are at best moderately effective. Growing evidence supports that, while an inflammatory pathology characterizes the early relapsing stage of multiple sclerosis, neurodegenerative pathology dominates the later progressive stage of the disease. Multiple sclerosis disease-modifying therapies currently in development attempt to specifically target the underlying pathology at each stage of the disease, while avoiding frequent self-injection. These include a variety of oral medications and monoclonal antibodies to reduce inflammation in relapsing multiple sclerosis and agents intended to promote neuroprotection and neurorepair in progressive multiple sclerosis. Although newer therapies for relapsing MS have the potential to be more effective and easier to administer than current therapies, they also carry greater risks. Effective treatments for progressive multiple sclerosis are still being sought.2009 Spain et al; licensee BioMed Central Ltd.
UR - http://www.scopus.com/inward/record.url?scp=73149094510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73149094510&partnerID=8YFLogxK
U2 - 10.1186/1741-7015-7-74
DO - 10.1186/1741-7015-7-74
M3 - Short survey
C2 - 19968863
AN - SCOPUS:73149094510
SN - 1741-7015
VL - 7
JO - BMC Medicine
JF - BMC Medicine
M1 - 74
ER -